Results 81 to 90 of about 2,525 (153)

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam

Journal of Global Antimicrobial Resistance
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K.
Peiyao Jia, Pengcheng Li, Wei Yu, Xiaobing Chu, Hui Zhang, Jingjia Zhang, Wei Kang, Ge Zhang, Qian Zhang, Shiyu Chen, Yingchun Xu, Qiwen Yang   +11 more
doaj   +1 more source

Combating Metallo-β-Lactamase-Producing Pseudomonas aeruginosa: The Fractional Inhibitory Concentration Index as a Tool to Evaluate Antibiotic Synergy

Antibiotics
Background: Multi-drug-resistant Gram-negative bacteria producing metallo-β-lactamase are an increasing concern. Here, we described three cases of infection due to difficult-to-treat and drug-resistant P.
Guido Granata, Carolina Venditti, Claudia Rotondo, Valentina Dimartino, Silvia D’Arezzo, Assunta Gallo, Gabriella Parisi, Alessandro Capone, Carla Fontana, Stefania Cicalini   +9 more
doaj   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

Journal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm, Laura Czerkster Antochevis, Cibele Massotti Magagnin, Beatriz Arns, Tarsila Vieceli, Dariane Castro Pereira, Larissa Lutz, Ândrea Celestino de Souza, Jéssica Nesello dos Santos, Rafaela Ramalho Guerra, Gregory S. Medeiros, Lucas Santoro, Diego R. Falci, Maria Helena Rigatto, Afonso Luís Barth, Andreza Francisco Martins, Alexandre Prehn Zavascki   +16 more
doaj   +1 more source

Antimicrobial activity of cephamycins and β-lactam/β-lactamase inhibitors against ESBL-producing Escherichia coli and Klebsiella pneumoniae under standard and high bacterial inocula

Scientific Reports
This study investigated the in vitro antimicrobial activity of cephamycins and novel β-lactam/β-lactamase inhibitor combinations, against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates.
Yu Mi Wi, Ji Young Choi, Da Eun Lee, So Hyun Jun, Ki Tae Kwon, Kwan Soo Ko   +5 more
doaj   +1 more source

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)

Infectious Diseases and Therapy
Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism.
Isabel Machuca, Arantxa Dominguez, Rosario Amaya, Cristina Arjona, Irene Gracia-Ahufinger, Maravillas Carralon, Rosa Giron, Isabel Gea, Natividad De Benito, Andres Martin, Fatima Galan, Jose Antonio Martinez, Rayden Iglesias, Jaume Revuelto, Juan Jose Caston, Angela Cano, Elisa Ruiz-Arabi, Luis Martínez-Martínez, Julian Torre-Cisneros   +18 more
doaj   +1 more source

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. [PDF]

Antimicrob Agents Chemother
Patel M, Nieddu G, DeRyke CA, Young K, Chen LF, Paschke A, Rizk ML, Gheyas F.   +7 more
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source

Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE). [PDF]

Antimicrob Agents Chemother
Wangchinda W, Wu JY, Abbo LM, Ackley R, Bartley P, Gilboa M, Harrington J, Jaffa R, Klatt ME, Kline EG, Kubat RC, Lepak AJ, McCreary EK, Miller WR, Pearson JC, Shah S, Tran TT, Vega A, Vendetti M, Yucel E, Pogue JM, Shields RK.   +21 more
europepmc   +1 more source

From bugs to bots: learning infectious diseases in the AI era. [PDF]

Antimicrob Steward Healthc Epidemiol
Rodriguez-Nava G.
europepmc   +1 more source

Phenotypic profile and molecular mechanism of resistance in carbapenemase-producing Enterobacterales and <i>Pseudomonas aeruginosa</i> isolates from Brazilian hospitals: implications for the introduction of imipenem-relebactam. [PDF]

Front Microbiol
Kurtz P, Del Peloso PF, Pribul BR, Albuquerque AM, Antunes BBP, Ramos GV, Bozza FA.   +6 more
europepmc   +1 more source